Author:
Seddon M,Wise R,Gillett A P,Livingston R
Abstract
The pharmacokinetics of the new cephalosporin Ro-13-9904 were studied in six healthy male volunteers receiving a 500-mg dose as a bolus intravenously. Tissue penetration of the antibiotic was estimated by using a cantharides blister method. The data obtained fitted a two-compartment open model. The mean elimination half-life was about 8 h, which is considerably longer than that of other beta-lactam compounds. The distribution volume was 4.3 liters in the central compartment. Levels of Ro 13-9904 in blister fluid exceeded those in serum after 6.5 h. Approximately 60% of the antibiotic was excreted in the urine.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference9 articles.
1. Beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin;Fu K. P.;Antimicrob. Agents Chemother.,1978
2. Clinical pharmacokinetics;Greenblatt D. J.;N. Engl. J. Med.,1975
3. Human pharmacology of cefotaxime (HR 756), a new cephalosporin;Luthy R.;Antimicrob. Agents Chemother.,1979
4. Antibacterial activity of a new 1-oxa cephalosporin compared with that of other ,-lactam compounds;Neu H. C.;Antimicrob. Agents Chemother.,1979
5. Cefazolin, ein neues Breitspektrum-Antibioticum;Simon C.;Dtsch. Med. Wochenschr.,1973
Cited by
121 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献